Kedrion S.p.A.

Chronic immune thrombocytopenia (ITP) is the main therapeutic area reflected in Kedrion S.p.A.’s clinical research activity, with attention on adult patients living with persistent low platelet counts.

• Platelet count recovery
• Bleeding risk reduction
• Adult ITP management

The sponsor’s research interest centers on immunoglobulin-based treatment in autoimmune haematology, particularly in the setting of thrombocytopenia.